ESMO Virtual Congress 2020 Press Releases

Viewing 1-14 of 14 articles

ESMO 2020: Two-Pronged Attack Using New Targeted Drug Could Treat ‘Addicted’ Prostate Cancers

Exelixis Announces Results from Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab

New First-Line Treatment Option for Metastatic Kidney Cancer, According to Results of Phase 3 Study

Nivolumab in Combination with Cabozantinib Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial

BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine

Belong.Life Releases Real-World Evidence Data of Financial Toxicity in Cancer Patients Receiving Immunotherapy

Four-Year Data Continue to Show Superior, Long-Term Survival Benefit with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

COVID-19 Pandemic Halts Cancer Care and Damages Oncologists’ Wellbeing

Clovis Oncology To Highlight Data For Its Three Portfolio Compounds At The ESMO Virtual Congress 2020

Study Highlights Possible Causes of Racial Disparities in Prostate Cancer Deaths

AstraZeneca Aims to Transform Cancer Treatment and Advance Clinical Practice with Data Presented at ESMO 2020

Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need

Bayer to Present New Data from Evolving Oncology Portfolio at ESMO 2020

Pivotal Studies for Pembrolizumab and Olaparib Selected for ESMO Presidential Symposium Sessions